078650 — G9Pharma Co Balance Sheet
0.000.00%
- KR₩135m
- KR₩23bn
- KR₩679m
Annual balance sheet for G9Pharma Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 11,227 | 331 | 4,673 | 111 | 1,839 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5,780 | 7,037 | 4,357 | 3,895 | 457 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 25,319 | 23,393 | 30,211 | 21,835 | 2,694 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 48,273 | 72,157 | 45,981 | 29,515 | 108 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 75,066 | 97,272 | 78,007 | 53,199 | 5,293 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 30,782 | 40,620 | 45,400 | 42,455 | 37,817 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 42,867 | 46,841 | 57,311 | 59,510 | 37,989 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 32,200 | 50,432 | 20,696 | -6,311 | -32,696 |
Total Liabilities & Shareholders' Equity | 75,066 | 97,272 | 78,007 | 53,199 | 5,293 |
Total Common Shares Outstanding |